OSAT yields 53.33% · ABBV yields 3.06%● Live data
📍 OSAT pulled ahead of the other in Year 1
Combined, OSAT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OSAT + ABBV for your $10,000?
Orbsat Corp., together with its subsidiaries, provides mobile satellite services (MSS) solutions for satellite-enabled voice, data, personnel and asset tracking, machine-to-machine, and Internet of Things (IoT) connectivity services in the United States and internationally. Its solutions include satellite communications, IoT tracking, and Internet, as well as emergency locator beacons. The company also provides tracking and monitoring solutions using automatic identification system, 2G-5G, push-to-talk, and two-way radio technology; and sells MSS related equipment. In addition, it operates GTCTrack, a subscription-based mapping and tracking portal that provides cloud-based data visualization and management platform that allow managers to track, command, and control assets in near-real-time; and a short-term rental service for customers to use equipment for a limited time period. The company provides its solutions for businesses, governments, military, humanitarian organizations, and individual users to communicate, connect to internet, track and monitor remote assets and lone workers, or request SOS assistance via satellite. It offers its products and services directly to end users and reseller networks; operates e-commerce websites that offer a range of MSS products and solutions; and offers portable satellite voice, data, and tracking solutions through various third-party e-commerce storefronts. The company was formerly known as Orbital Tracking Corp and changed its name to Orbsat Corp. in August 2019. Orbsat Corp. was incorporated in 1997 and is headquartered in Aventura, Florida.
Full OSAT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.